科研之友
微信
新浪微博
Facebook
分享链接
摘要
New therapeutic agents, i.e., biologicals, may induce a variety of novel cutaneous adverse reactions (CAR), which hardly can be assigned to existing classification systems. Basing on clinical examples, we present a recently established classification system for CAR to novel drugs. In addition, management strategies for CAR to tumor necrosis factor-alpha antagonists and to epidermal growth factor receptor inhibitors are discussed.
- 出版日期2012-8
